LGC introduces new drug candidate for Osteoarthritis from bio-venture ICM

Gene Therapy ahead of Phase 1 clinical trials in the US and Australia

ICM announced on the 22nd that it has signed a contract to transfer the development and commercialization rights in Korea and China for ICM-203, an adeno-associated virus vector-based drug candidate ICM-203 loaded and inserted with a related gene to treat Osteoarthritis.



full text : https://www.mk.co.kr/news/stock/view/2020/12/1309238/

Leave a comment

You must be logged in to post a comment.